is semaglutide in short supply FDA says Ozempic, Wegovy are not anymore, which could impact prices FDA ends semaglutide shortage, closing

GLP-1s by year and indication GLP-1s by indication and year GLP-1 pipeline FAQs On March 19, 2026, the FDA approved a new, high-dose semaglutide (Wegovy HD) injection (7.2 mg) for once-weekly, subcutaneous (SC) administration for weight reduction and long-term maintenance

Your body has adapted to GLP-1 activation from semaglutide, but it has never experienced GIP activation

On This Page Indications and Usage Dosage and Administration Dosage Forms and Strengths Contraindications Warnings and Precautions Adverse Reactions/Side Effects Drug Interactions Use In Specific Populations Overdosage Description Clinical Pharmacology Nonclinical Toxicology Clinical Studies How Supplied/Storage and Handling Patient Counseling Information Medication Guide Highlights of Prescribing Information RYBELSUS (semaglutide) tablets, for oral use Initial U.S

Additionally, no human clinical trials of SQOR inhibitors have been initiated to date

Xu Y, Propson NE, Du S, Xiong W, Zheng H